Understanding and Ameliorating the TTR Amyloidoses

Protein Misfolding Diseases: Current and Emerging Principles and Therapies

Volumn , Issue , 2010, Pages 967-1003

  Johnson, Steven M ^a   Wiseman, Luke ^a   Paulsson, Johan F ^a,b   Choi, Sungwook ^a   Powers, Evan T ^a   Buxbaum, Joel N ^a   Kelly, Jeffery W ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cellular proteostasis network influence on TTR amyloidogenesis; Transthyretin amyloidogenesis or amyloid fibril formation causing a discrete set of human amyloid diseases; understanding and ameliorating the transthyretin (TTR) amyloidoses

Indexed keywords

EID: 84886147089     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470572702.ch45     Document Type: Chapter

References (185)

1. Selkoe, D.J. (2003). Folding proteins in fatal ways. Nature, 426, 900-904.
2. Westermark, P., Andersson, A., Westermark, G.T. (2005). Is aggregated IAPP a cause of beta-cell failure in transplanted human pancreatic islets? Curr Diabetes Rep, 5, 184-188.
3. Cohen, F.E., Kelly, J.W. (2003). Therapeutic approaches to protein-misfolding diseases. Nature, 426, 905-909.
4. Dobson, C.M. (2003). Protein folding and misfolding. Nature, 426, 884-890.
5. Kelly, J.W. (1996). Alternative conformations of amyloidogenic proteins govern their behavior. Curr Op Struct Biol, 6, 11-17.
6. Westermark, P., Benson, M.D., Buxbaum, J.N., Cohen, A.S., Frangione, B., Ikeda, S.I., Masters, C.L., Merlini, G., Saraiva, M.J., Sipe, J.D. (2007). A primer of amyloid nomenclature. Amyloid, 14, 179-183.
7. Sipe, J.D. (1992). Amyloidosis. Ann Rev Biochem, 61, 947-975.
8. Sipe, J.D. (1994). Amyloidosis. Crit Rev Clin Lab Sci, 31, 325-354.
9. Buxbaum, J.N., Tagoe, C.E. (2000). The genetics of the amyloidoses. Annu Rev Med, 51, 543-569.
10. Jahn, T.R., Radford, S.E. (2008). Folding versus aggregation: polypeptide conformations on competing pathways. Arch Biochem Biophys, 469, 100-117.
11. Pepys, M.B. (2001). Pathogenesis, diagnosis and treatment of systemic amyloidosis. Philos Trans R Soc Lond Ser B, 356, 203-211.
12. Benson, M.D. (1989). Familial amyloidotic polyneuropathy. TIBS, 12, 88-92.
13. Walsh, D.M., Selkoe, D.J. (2007). Abeta oligomers: a decade of discovery. J Neurochem, 101, 1172-1184.
14. Lambert, M.P., Barlow, A.K., Chromy, B.A., Edwards, C., Freed, R., Liosatos, M., Morgan, T.E., Rozovsky, I., Trommer, B., Viola, K.L., et al. (1998). Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A, 95, 6448-6453.
15. Lashuel, H.A., Wurth, C., Woo, L., Kelly, J.W. (1999). The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions. Biochemistry, 38, 13560-13573.
16. Lashuel, H.A., LaBrenz, S.R., Woo, L., Serpell, L., Kelly, J.W. (2000). Protofilaments, filaments, ribbons, and fibrils from peptidomimetic self-assembly: implications for amyloid fibril formation and materials science. J Am Chem Soc, 122, 5262-5277.
17. Lashuel, H.A., Hartley, D., Petre, B.M., Walz, T., Lansbury, P.T., Jr. (2002). Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature, 418, 291.
18. Pepys, M.B. (1988). Amyloidosis. In Immunological Diseases (Samter, M., Ed.), Little, Brown, Boston.
19. Tan, S.Y., Pepys, M.B. (1994). Amyloidosis. Histopathology, 25, 403-414.
20. Sousa, M.M., Cardoso, I., Fernandes, R., Guimaraes, A., Saraiva, M.J. (2001). Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am J Pathol, 159, 1993-2000.
21. Kelly, J.W., Colon, W., Lai, Z., Lashuel, H.A., McCulloch, J., McCutchen, S.L., Miroy, G.J., Peterson, S.A. (1997). Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid. Adv Protein Chem, 50, 161-181.
22. Lashuel, H.A., Lai, Z., Kelly, J.W. (1998). Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wildtype, V30M, and L55P amyloid fibril formation. Biochemistry, 37, 17851-17864.
23. Liu, K., Cho, H.S., Lashuel, H.A., Kelly, J.W., Wemmer, D.E. (2000). A glimpse of a possible amyloidogenic intermediate of transthyretin. Nat Struct Biol, 7, 754-757.
24. Bieschke, J., Zhang, Q., Powers, E.T., Lerner, R.A., Kelly, J.W. (2005). Oxidative metabolites accelerate Alzheimer's amyloidogenesis by a two-step mechanism, eliminating the requirement for nucleation. Biochemistry, 44, 4977-4983.
25. Zhang, Q., Powers, E.T., Nieva, J., Huff, M.E., Dendle, M.A., Bieschke, J., Glabe, C.G., Eschenmoser, A., Wentworth, P., Jr., Lerner, R.A., Kelly, J.W. (2004). Metabolite-initiated protein misfolding may trigger Alzheimer's disease. Proc Natl Acad Sci U S A, 101, 4752-4757.
26. Kelly, J.W. (1998). The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr Opin Struct Biol, 8, 101-106.
27. Teng, M.-H., Yin, J.-Y., Vidal, R., Ghiso, J., Kumar, A., Rabenou, R., Shah, A., Jacobson, D.R., Tagoe, C., Gallo, G., Buxbaum, J. (2001). Amyloid and nonfibrillar deposits in mice transgenic for wild-type human transthyretin: a possible model for senile systemic amyloidosis. Lab Invest, 81, 385-396.
28. Reixach, N., Deechongkit, S., Jiang, X., Kelly, J.W., Buxbaum, J.N. (2004). Tissue damage in the amyloidoses: transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci U S A, 101, 2817-2822.
29. Shankar, G.M., Li, S., Mehta, T.H., Garcia-Munoz, A., Shepardson, N.E., Smith, I., Brett, F.M., Farrell, M.A., Rowan, M.J., Lemere, C.A., et al. (2008). Amyloidbeta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med, 14, 837-842.
30. Silveira, J.R., Raymond, G.J., Hughson, A.G., Race, R.E., Sim, V.L., Hayes, S.F., Caughey, B. (2005). The most infectious prion protein particles. Nature, 437, 257-261.
31. Hardy, J.A., Higgins, G. (1992). Alzheimer's disease: the amyloid cascade hypothesis. Science, 256, 184-185.
32. Tanzi, R.E., Bertram, L. (2005). Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell, 120, 545-555.
33. Bertram, L., Tanzi, R.E. (2008). Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci, 9, 768-778.
34. Selkoe, D.J. (2006). The ups and downs of Abeta. Nat Med, 12, 758-759.
35. Hammarstrom, P., Wiseman, R.L., Powers, E.T., Kelly, J.W. (2003). Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science, 299, 713-716.
36. Hammarstrom, P., Schneider, F., Kelly, J.W. (2001). Trans-suppression of misfolding in an amyloid disease. Science, 293, 2459-2462.
37. Coelho, T., Carvalho, M., Saraiva, M.J., Alves, I., Almeida, M.R., Costa, P.P. (1993). A strikingly benign evolution of FAP in an individual found to be a compound heterozygote for two TTR mutations: TTR Met 30 and TTR Met 119. J Rheumatol, 20, 179.
38. Golde, T.E., Janus, C. (2005). Homing in on intracellular Abeta? Neuron, 45, 639-642.
39. Gouras, G.K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J.P., Haroutunian, V., Buxbaum, J.D., Xu, H., et al. (2000). Intraneuronal Abeta42 accumulation in human brain. Am J Pathol, 156, 15-20.
40. LaFerla, F.M., Troncoso, J.C., Strickland, D.K., Kawas, C.H., Jay, G. (1997). Neuronal cell death in Alzheimer's disease correlates with apoE uptake and intracellular Abeta stabilization. J Clin Invest, 100, 310-320.
41. Wirths, O., Multhaup, G., Czech, C., Blanchard, V., Moussaoui, S., Tremp, G., Pradier, L., Beyreuther, K., Bayer, T.A. (2001). Intraneuronal Abeta accumulation precedes plaque formation in beta-amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci Lett, 306, 116-120.
42. Sekijima, Y., Wiseman, R.L., Matteson, J., Hammarstrom, P., Miller, S.R., Sawkar, A.R., Balch, W.E., Kelly, J.W. (2005). The biological and chemical basis for tissue-selective amyloid disease. Cell, 121, 73-85.
43. Puchtler, H., Sweat, F., Levine, M. (1962). On the binding of Congo Red by amyloid. J Histochem Cytochem, 10, 355.
44. LeVine, H., III. (1997). Stopped-flow kinetics reveal multiple phases of thioflavin T binding to Alzheimer beta(1-40) amyloid fibrils. Arch Biochem Biophys, 342, 306-316.
45. Nilsson, K.P.R., Aslund, A., Berg, I., Nystrom, S., Konradsson, P., Herland, A., Inganas, O., Stabo-Eeg, F., Lindgren, M., Westermark Gunilla, T., et al. (2007). Imaging distinct conformational states of amyloid-beta fibrils in Alzheimer's disease using novel luminescent probes. ACS Chem Biol, 2, 553-560.
46. Eaton, W.A., Hofrichter, J. (1990). Sickle cell hemoglobin polymerization. Adv Protein Chem, 40, 63-279.
47. Colon, W., Kelly, J.W. (1991). Transthyretin acid induced denaturation is required for amyloid fibril formation in vitro. In Applications of Enzyme Biotechnology (Kelly, J.W., Balwin, T.O., Eds.), Plenum Press, New York.
48. Colon, W., Kelly, J.W. (1992). Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry, 31, 8654-8660.
49. Lai, Z., Colon, W., Kelly, J.W. (1996). The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate which can self-assemble into amyloid. Biochemistry, 35, 6470-6482.
50. McCutchen, S., Colon, W., Kelly, J.W. (1993). Transthyretin mutation Leu-55-Pro significantly alters tetramer stability and increases amyloidogenicity. Biochemistry, 32, 12119-12127.
51. McCutchen, S.L., Lai, Z., Miroy, G., Kelly, J.W., Colon, W. (1995). Comparison of lethal and non-lethal transthyretin variants and their relationship to amyloid disease. Biochemistry, 34, 13527-13536.
52. Jiang, X., Smith, C.S., Petrassi, H.M., Hammarstrom, P., White, J.T., Sacchettini, J.C., Kelly, J.W. (2001). An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured. Biochemistry, 40, 11442-11452.
53. Hurle, M.R., Helms, L.R., Li, L., Chan, W., Wetzel, R. (1994). A role for destabilizing amino acid replacements in light chain amyloidosis. Proc Natl Acad Sci USA, 91, 5446-5450.
54. Wetzel, R. (1996). For protein misassembly, its the "I" decade. Cell, 86, 699-702.
55. Booth, D.R., Sunde, M., Bellotti, V., Robinson, C.V., Hutchinson, W.L., Fraser, P.E., Hawkins, P.N., Dobson, C.M., Radford, S.E., Blake, C.C.F., Pepys, M.B. (1997). Instability, unfolding and aggregation of human lysosozyme variants underlying amyloid fibrillogenesis. Nature, 385, 787-793.
56. Powers, E.T., Powers, D.L. (2008). Mechanisms of protein fibril formation: nucleated polymerization with competing off-pathway aggregation. Biophys J, 94, 379-391.
57. Ferrone, F. (1999). Analysis of protein aggregation kinetics. Methods Enzymol, 309, 256-274.
58. Jarrett, J., Lansbury, P.T. (1993). Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell, 73, 1055-1058.
59. Xue, W.-F., Homans, S.W., Radford, S.E. (2008). Systematic analysis of nucleation-dependent polymerization reveals new insights into the mechanism of amyloid self-assembly. Proc Natl Acad Sci U S A, 105, 8926-8931.
60. Lundmark, K., Westermark, G.T., Nystrom, S., Murphy, C.L., Solomon, A., Westermark, P. (2002). Transmissibility of systemic amyloidosis by a prion-like mechanism. Proc Natl Acad Sci U S A, 99, 6979-6984.
61. Bieschke, J., Siegel Sarah, J., Fu, Y., Kelly, J.W. (2008). Alzheimer's Abeta peptides containing an isostructural backbone mutation afford distinct aggregate morphologies but analogous cytotoxicity: evidence for a common low-abundance toxic structure(s)? Biochemistry, 47, 50-59.
62. Bieschke, J., Zhang, Q., Bosco, D.A., Lerner, R.A., Powers, E.T., Wentworth, P., Jr., Kelly, J.W. (2006). Small molecule oxidation products trigger disease-associated protein misfolding. Acc Chem Res, 39, 611-619.
63. Siegel, S.J., Bieschke, J., Powers, E.T., Kelly, J.W. (2007). The oxidative stress metabolite 4-hydroxynonenal promotes Alzheimer protofibril formation. Biochemistry, 46, 1503-1510.
64. Stewart, C.R., Wilson, L.M., Zhang, Q., Pham, C.L.L., Waddington, L.J., Staples, M.K., Stapleton, D., Kelly, J.W., Howlett, G.J. (2007). Oxidized cholesterol metabolites found in human atherosclerotic lesions promote apolipoprotein C-II amyloid fibril formation. Biochemistry, 46, 5552-5561.
65. Blake, C.C., Geisow, M.J., Oatley, S.J., Rerat, B., Rerat, C. (1978). Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A ° J Mol Biol, 121, 339-356.
66. Blake, C.C., Geisow, M.J., Swan, I.D., Rerat, C., Rerat, B. (1974). Structure of human plasma prealbumin at 2-5 A ° resolution: a preliminary report on the polypeptide chain conformation, quaternary structure and thyroxine binding. J Mol Biol, 88, 1-12.
67. Klabunde, T., Petrassi, H.M., Oza, V.B., Raman, P., Kelly, J.W., Sacchettini, J.C. (2000). Rational design of potent human transthyretin amyloid disease inhibitors. Nat Struct Biol, 7, 312-321.
68. Hamilton, J.A., Benson, M.D. (2001). Transthyretin: a review from a structural perspective. Cell Mol Life Sci, 58, 1491-1521.
69. Hornberg, A., Eneqvist, T., Olofsson, A., Lundgren, E., Sauer-Eriksson, A.E. (2000). A comparative analysis of 23 structures of the amyloidogenic protein transthyretin. J Mol Biol, 302, 649-669.
70. Correa, C.R., Burini, R.C. (2000). Plasma acute-phase reactive proteins. J Bras Patol, 36, 26-34.
71. Johnson, S.M., Wiseman, R.L., Sekijima, Y., Green, N.S., Adamski-Werner, S.L., Kelly, J.W. (2005). Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc Chem Res,. 38, 911-921.
72. Monaco, H.L., Rizzi, M., Coda, A. (1995). Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein. Science, 268, 1039-1041.
73. Zanotti, G., Berni, R. (2004). Plasma retinol-binding protein: structure and interactions with retinol, retinoids, and transthyretin. Vitam Horm, 69, 271-295.
74. Kopelman, M., Mokady, S., Cogan, U. (1976). Comparative studies of human and chicken retinol-binding proteins and prealbumins. Biochim Biophys Acta, 439, 442-448.
75. White, J.T., Kelly, J.W. (2001). Support for the multigenic hypothesis of amyloidosis: the binding stoichiometry of retinol-binding protein, vitamin A, and thyroid hormone influences transthyretin amyloidogenicity in vitro. Proc Natl Acad Sci U S A, 98, 13019-13024.
76. Watanabe, C.M., Wolffram, S., Ader, P., Rimbach, G., Packer, L., Maguire, J.J., Schultz, P.G., Gohil, K. (2001). The in vivo neuromodulatory effects of the herbal medicine Ginkgo biloba. Proc Natl Acad Sci U S A, 98, 6577-6580.
77. Stein, T.D., Anders, N.J., DeCarli, C., Chan, S.L., Mattson, M.P., Johnson, J.A. (2004). Neutralization of transthyretin reverses the neuroprotective effects of secreted amyloid precursor protein (APP) in APPSw mice resulting in tau phosphorylation and loss of hippocampal neurons: support for the amyloid hypothesis. J Neurosci, 24, 7707-7717.
78. Stein, T.D., Johnson, J.A. (2002). Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. J Neurosci, 22, 7380-7388.
79. Southwell, B.R., Tu, G.F., Duan, W., Achen, M., Harms, P.J., Aldred, A.R., Richardson, S.J., Thomas, T., Pettersson, T.M., Schreiber, G. (1992). Cerebral expression of transthyretin: evolution, ontogeny and function. Acta Med Austriaca, 19 Suppl 1, 28-31.
80. Herbert, J., Wilcox, J.N., Pham, K.-T.C., Fremeau, R.T., Zeviani, M., Dwork, A., Sopprano, D.R., Makover, A., Goodman, D.S., Zimmerman, E.A., et al. (1986). Transthyretin: a choroid plexus-specific transport protein in the human brain. Neurology, 36, 900-911.
81. Martone, R.L., Herbert, J., Dwork, A., Schon, E.A. (1988). Transthyretin is synthesized in the mammalian eye. Biochem Biophys Res Commun, 151, 905-912.
82. Hovatta, I., Zapala, M.A., Broide, R.S., Schadt, E.E., Libiger, O., Schork, N.J., Lockhart, D.J., Barlow, C. (2007). DNA variation and brain region-specific expression profiles exhibit different relationships between inbred mouse strains: implications for eQTL mapping studies. Genome Biol, 8, R25.
83. Murakami, T., Ohsawa, Y., Sunada, Y. (2008). The transthyretin gene is expressed in human and rodent dorsal root ganglia. Neurosci Lett, 436, 335-339.
84. Buxbaum, J.N., Ye, Z., Reixach, N., Friske, L., Levy, C., Das, P., Golde, T., Masliah, E., Roberts, A.R., Bartfai, T. (2008). Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Abeta toxicity. Proc Natl Acad Sci U S A, 105, 2681-2686.
85. Sousa, J.C., Grandela, C., Fernandez-Ruiz, J., de Miguel, R., de Sousa, L.,Magalhaes, A.I., Saraiva, M.J., Sousa, N., Palha, J.A. (2004). Transthyretin is involved in depression-like behaviour and exploratory activity. J Neurochem, 88, 1052-1058.
86. Fleming, C.E., Saraiva, M.J., Sousa, M.M. (2007). Transthyretin enhances nerve regeneration. J Neurochem, 103, 831-839.
87. Richardson, S.J., Lemkine, G.F., Alfama, G., Hassani, Z., Demeneix, B.A. (2007). Cell division and apoptosis in the adult neural stem cell niche are differentially affected in transthyretin null mice. Neurosci Lett, 421, 234-238.
88. Lai, Z., McCulloch, J., Kelly, J.W. (1997). GdnHCl-induced denaturation and refolding of transthyretin exhibits a marked hysteresis: equilibria with high kinetic barriers. Biochemistry, 36, 10230-10239.
89. Schneider, F., Hammarstrom, P., Kelly, J.W. (2001). Transthyretin slowly exchanges subunits under physiological conditions: a convenient chromatographic method to study subunit exchange in oligomeric proteins. Protein Sci, 10, 1606-1613.
90. Reixach, N., Foss, T.R., Santelli, E., Pascual, J., Kelly, J.W., Buxbaum, J.N. (2008). Human-murine transthyretin heterotetramers are kinetically stable and nonamyloidogenic. a lesson in the generation of transgenic models of diseases involving oligomeric proteins. J Biol Chem, 283, 2098-2107.
91. Jiang, X., Buxbaum, J.N., Kelly, J.W. (2001). The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis. Proc Natl Acad Sci U S A, 98, 14943-14948.
92. Hurshman Babbes, A.R., Powers, E.T., Kelly, J.W. (2008). Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis. Biochemistry, 47, 6969-6984.
93. Hurshman, A.R., White, J.T., Powers, E.T., Kelly, J.W. (2004). Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. Biochemistry, 43, 7365-7381.
94. Hammarstrom, P., Jiang, X., Deechongkit, S., Kelly, J.W. (2001). Anion shielding of electrostatic repulsions in transthyretin modulates stability and amyloidosis: insight into the chaotrope unfolding dichotomy. Biochemistry, 40, 11453-11459.
95. Foss, T.R., Kelker, M.S., Wiseman, R.L., Wilson, I.A., Kelly, J.W. (2005). Kinetic stabilization of the native state by protein engineering: implications for inhibition of transthyretin amyloidogenesis. J Mol Biol, 347, 841-854.
96. Hammarstrom, P., Jiang, X., Hurshman, A.R., Powers, E.T., Kelly, J.W. (2002). Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity. Proc Natl Acad Sci U S A, 99 (Suppl 4), 16427-16432.
97. Wiseman, R.L., Green, N.S., Kelly, J.W. (2005). Kinetic stabilization of an oligomeric protein under physiological conditions demonstrated by a lack of subunit exchange: implications for transthyretin amyloidosis. Biochemistry, 44, 9265-9274.
98. Palaninathan, S.K., Mohamedmohaideen, N.N., Snee, W.C., Kelly, J.W., Sacchettini, J.C. (2008). Structural insight into pH-induced conformational changes within the native human transthyretin tetramer. J Mol Biol, 382, 1157-1167.
99. Liu, K., Cho, H.S., Hoyt, D.W., Nguyen, T.N., Olds, P., Kelly, J.W., Wemmer, D.E. (2000). Deuterium-proton exchange on the native wild-type transthyretin tetramer identifies the stable core of the individual subunits and indicates mobility at the subunit interface. J Mol Biol, 303, 555-565.
100. Liu, K., Kelly, J.W., Wemmer, D.E. (2002). Native state hydrogen exchange study of suppressor and pathogenic variants of transthyretin. J Mol Biol, 320, 821-832.
101. Hammarstrom, P., Sekijima, Y., White, J.T., Wiseman, R.L., Lim, A., Costello, C.E., Altland, K., Garzuly, F., Budka, H., Kelly, J.W. (2003). D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis? Biochemistry, 42, 6656-6663.
102. Snyder, S.W., Ladror, U.S., Wade, W.S., Wang, G.T., Barrett, L.W., Matayoshi, E.D., Huffaker, H.J., Krafft, G.A., Holzman, T.F. (1994). Amyloid-b aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. Biophys J, 67, 1216-1228.
103. Harper, J.D., Wong, S.S., Lieber, C.M., Lasbury, P.T. (1997). Observation of metastable A-beta amyloid protofibrils by atomic force microscopy. Chem Biol, 4, 119-125.
104. Wang, H.W., Pasternak, J.F., Kuo, H., Ristic, H., Lambert, M.P., Chromy, B., Viola, K.L., Klein, W.L., Stine, W.B., Krafft, G.A., Trommer, B.L. (2002). Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res, 924, 133-140.
105. Gong, Y., Chang, L., Viola, K.L., Lacor, P.N., Lambert, M.P., Finch, C.E., Krafft, G.A., Klein, W.L. (2003). Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A, 100, 10417-10422.
106. Cohen, E., Bieschke, J., Perciavalle, R.M., Kelly, J.W., Dillin, A. (2006). Opposing activities protect against age-onset proteotoxicity. Science, 313, 1604-1610.
107. Serio, T.R., Cashikar, A.G., Kowal, A.S., Sawicki, G.J., Moslehi, J.J., Serpell, L., Arnsdorf, M.F., Lindquist, S.L. (2000). Nucleated conformational conversion and the replication of conformational information by a prion determinant. Science, 289, 1317-1321.
108. Blake, C., Serpell, L. (1996). Synchrotron X-ray studies suggest that the core of the transthyretin amyloid fibril is a continuous beta-sheet helix. Structure, 4, 989-998.
109. Jacobson, D.R., Pastore, R.D., Yaghoubian, R., Kane, I., Gallo, G., Buck, F.S., Buxbaum, J.N. (1997). Variant-sequence transthyretin (isoleucine 122) in lateonset cardiac amyloidosis in black Americans. N Engl J Med, 336, 466-473.
110. Westermark, P., Sletten, K., Johansson, B., Cornwell, G.G. (1990). Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci U S A, 87, 2843-2845.
111. Cornwell, G.C., Sletten, K., Johansson, B., Westermark, P. (1988). Evidence that the amyloid fibril protein in senile systemic amyloidosis is derived from normal prealbumin. Biochem Biophys Res Commun, 154, 648-653.
112. Tanskanen, M., Peuralinna, T., Polvikoski, T., Notkola, I.-L., Sulkava, R., Hardy, J., Singleton, A., Kiuru-Enari, S., Paetau, A., Tienari, P.J., Myllykangas, L. (2008). Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med, 40, 232-239.
113. Afolabi, I., Asl, K.H., Nakamura, M., Jacobs, P., Hendrie, H., Benson, M.D. (2000). Transthyretin isoleucine-122 mutation in African and American blacks. Amyloid, 7, 121-125.
114. Yamashita, T., Asl, K.H., Yazaki, M., Benson, M.D. (2005). A prospective evaluation of the transthyretin Ile122 allele frequency in an African-American population. Amyloid, 12, 127-130.
115. Andrade, C. (1952). A peculiar form of peripheral neuropathy: familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain, 75, 408-427.
116. Saraiva, M.J., Sousa, M.M., Cardoso, I., Fernandes, R. (2004). Familial amyloidotic polyneuropathy: protein aggregation in the peripheral nervous system. J Mol Neurosci, 23, 35-40.
117. Suhr, O.B., Hastrup Svendsen, I., Andersson, R., Danielsson, A., Holmgren, G., Ranlov, P.J. (2003). Hereditary transthyretin amyloidosis from a Scandinavian perspective. J Intern Med, 254, 225-235.
118. Suhr, O.B., Herlenius, G., Friman, S., Ericzon, B.G. (2000). Liver transplantation for hereditary transthyretin amyloidosis. Liver Transpl, 6, 263-276.
119. Coelho, T. (1996). Familial amyloid polyneuropathy: new developments in genetics and treatment. Curr Opin Neurol, 9, 355-359.
120. Ikeda, S., Nakazato, M., Ando, Y., Sobue, G. (2002). Familial transthyretin-type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity. Neurology, 58, 1001-1007.
121. Koike, H., Misu, K., Sugiura, M., Iijima, M., Mori, K., Yamamoto, M., Hattori, N., Mukai, E., Ando, Y., Ikeda, S., Sobue, G. (2004). Pathology of early-vs late-onset TTR Met30 familial amyloid polyneuropathy. Neurology, 63, 129-138.
122. Ando, Y., Suhr, O.B. (1998). Autonomic dysfunction in familial amyloidotic polyneuropathy (FAP). Amyloid, 5, 288-300.
123. Holmgren, G., Ando, Y., Wikstrom, L., Rydh, A., Suhr, O. (1997). Discordant symptoms in monozygotic twins with familial amyloidotic polyneuropathy (FAP) (TTR Met 30). Amyloid, 4, 178-180.
124. Sousa, A., Coelho, T., Barros, J., Sequeiros, J. (1995). Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in Povoa do Varzim and Vila do Conde (north of Portugal). Am J Med Genet, 60, 512-521.
125. Soares, M.L., Coelho, T., Sousa, A., Batalov, S., Conceicao, I., Sales-Luis, M.L., Ritchie, M.D., Williams, S.M., Nievergelt, C.M., Schork, N.J., et al. (2005). Susceptibility and modifier genes in Portuguese transthyretin V30M amyloid polyneuropathy: complexity in a single-gene disease. Hum Mol Genet, 14, 543-553.
126. Helgadottir, A., Manolescu, A., Thorleifsson, G., Gretarsdottir, S., Jonsdottir, H., Thorsteinsdottir, U., Samani, N.J., Gudmundsson, G., Grant, S.F., Thorgeirsson, G., et al. (2004). The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet, 36, 233-239.
127. Jacobson, D.R., Buxbaum, J.N. (1991). Genetic aspects of amyloidosis. Adv Hum Genet, 20, 69-123.
128. Jahoor, F., Reeds, P.J. (1999). The measurement of the rate of synthesis of liverderived plasma proteins. Methods Invest Amino Acid Protein Metab, 69-81.
129. Aldred, A.R., Brack, C.M., Schreiber, G. (1995). The cerebral expression of plasma protein genes in different species. Comp Biochem Physiol B, 111, 1-15.
130. Weisner, B., Roethig, H.J. (1983). The concentration of prealbumin in cerebrospinal fluid (CSF), indicator of CSF circulation disorders. Eur Neurol, 22, 96-105.
131. Santos, C.R., Anjos, L., Power, D.M. (2002). Transthyretin in fish: state of the art. Clin Chem Lab Med, 40, 1244-1249.
132. Balch, W.E., Morimoto, R.I., Dillin, A., Kelly, J.W. (2008). Adapting proteostasis for disease intervention. Science, 319, 916-919.
133. Miroy, G.J., Lai, Z., Lashuel, H., Peterson, S.A., Strang, C., Kelly, J.W. (1996). Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc Natl Acad Sci U S A, 93, 15051-15056.
134. Perlmutter, D.H. (2003). Alpha 1-antitrypsin deficiency: liver disease associated with retention of a mutant secretory glycoprotein in the endoplasmic reticulum. Methods Mol Biol, 232, 39-56.
135. Parfrey, H., Mahadeva, R., Lomas, D.A. (2003). Alpha 1-antitrypsin deficiency, liver disease and emphysema. Int J Biochem Cell Biol, 35, 1009-1014.
136. Suk, J.Y., Zhang, F., Balch, W.E., Linhardt, R.J., Kelly, J.W. (2006). Heparin accelerates gelsolin amyloidogenesis. Biochemistry, 45, 2234-2242.
137. Sekijima, Y., Hammarstrom, P., Matsumura, M., Shimizu, Y., Iwata, M., Tokuda, T., Ikeda, S., Kelly, J.W. (2003). Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology. Lab Invest, 83, 409-417.
138. Coelho, T., Chorao, R., Sausa, A., Alves, I., Torres, M.F., Saraiva, M.J. (1996). Compound heterozygotes of transthyretin Met30 and transthyretin Met119 are protected from the devastating effects of familial amyloid polyneuropathy. Neuromusc Disord, 6, 27.
139. Buxbaum, J., Tagoe, C., Gallo, G., Reixach, N., French, D. (2003). The pathogenesis of transthyretin tissue deposition: lessons from transgenic mice. Amyloid, 10, 2-6.
140. Teng, M.H., Yin, J.Y., Vidal, R., Ghiso, J., Kumar, A., Rabenou, R., Shah, A., Jacobson, D.R., Tagoe, C., Gallo, G., Buxbaum, J. (2001). Amyloid and nonfibrillar deposits in mice transgenic for wild-type human transthyretin: a possible model for senile systemic amyloidosis. Lab Invest, 81, 385-396.
141. Kohno, K., Palha, J.A., Miyakawa, K., Saraiva, M.J., Ito, S., Mabuchi, T., Blaner, W.S., Iijima, H., Tsukahara, S., Episkopou, V., et al. (1997). Analysis of amyloid deposition in a transgenic mouse model of homozygous familial amyloidotic polyneuropathy. Am J Pathol, 150, 1497-1508.
142. Tagoe, C.E., Reixach, N., Friske, L., Mustra, D., French, D., Gallo, G., Buxbaum, J.N. (2007). In vivo stabilization of mutant human transthyretin in transgenic mice. Amyloid, 14, 227-236.
143. Holmgren, G., Ericzon, B.G., Groth, C.G., Steen, L., Suhr, O., Andersen, O., Wallin, B. G., Seymour, A., Richardson, S., Hawkins, P.N. (1993). Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet, 341, 1113-1116.
144. Suhr, O.B., Holmgren, G., Lundgren, E. (2004). Gene therapy: lessons learned from liver transplantation for transthyretin-amyloidosis. Liver Transpl, 10, 1551-1553.
145. Herlenius, G., Wilczek, H.E., Larsson, M., Ericzon, B.G. (2004). Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation, 77, 64-71.
146. Stangou, A.J., Hawkins, P.N. (2004). Liver transplantation in transthyretin-related familial amyloid polyneuropathy. Curr Opin Neurol, 17, 615-620.
147. Olofsson, B.O., Backman, C., Karp, K., Suhr, O.B. (2002). Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type. Transplantation, 73, 745-751.
148. Hornsten, R., Wiklund, U., Olofsson, B.O., Jensen, S.M., Suhr, O.B. (2004). Liver transplantation does not prevent the development of life-threatening arrhythmia in familial amyloidotic polyneuropathy, Portuguese-type (ATTR Val30Met) patients. Transplantation, 78, 112-116.
149. Ando, Y., Terazaki, H., Nakamura, M., Ando, E., Haraoka, K., Yamashita, T., Ueda, M., Okabe, H., Sasaki, Y., Tanihara, H., et al. (2004). A different amyloid formation mechanism: de novo oculoleptomeningeal amyloid deposits after liver transplantation. Transplantation, 77, 345-349.
150. Ando, Y., Ericzon, B.G., Suhr, O.B., Tashima, K., Ando, M. (1997). Reuse of a Japanese familial amyloidotic polyneuropathy patient's liver for a cancer patient: the domino liver transplantation procedure. Intern Med, 36, 847.
151. Azoulay, D., Samuel, D., Castaing, D., Adam, R., Adams, D., Said, G., Bismuth, H. (1999). Domino liver transplants for metabolic disorders: experience with familial amyloidotic polyneuropathy. J Am Coll Surg, 189, 584-593.
152. Ericzon, B.G., Larsson, M., Wilczek, H.E. (2008). Domino liver transplantation: risks and benefits. Transplant Proc, 40, 1130-1131.
153. Stangou, A.J., Heaton, N.D., Hawkins, P.N. (2005). Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation. N Engl J Med, 352, 2356.
154. Bittencourt Paulo, L., Couto Claudia, A., Leitao Regina Maria, C., Siqueira Sheila, A., Farias Alberto, Q., Massarollo Paulo Celso, B., Mies, S. (2002). No evidence of de novo amyloidosis in recipients of domino liver transplantation: 12 to 40 (mean 24) month follow-up. Amyloid, 9, 194-196.
155. Obayashi, K., Yamashita, T., Ueda, M., Nakamura, M., Asonuma, K., Inomata, Y., Uchino, M., Tanaka, K., Ando, Y. (2008). Amyloid neuropathy in a Japanese domino liver-transplanted recipient. Int Symp Amyloidosis, 11th, 172-174.
156. Schmidt, H.H., Nashan, B., Propsting, M.J., Nakazato, M., Flemming, P., Kubicka, S., Boker, K., Pichlmayr, R., Manns, M.P. (1999). Familial amyloidotic polyneuropathy: domino liver transplantation. J Hepatol, 30, 293-298.
157. Takei, Y.-I., Gono, T., Yazaki, M., Ikeda, S.-I., Ikegami, T., Hashikura, Y., Miyagawa, S.-I., Hoshii, Y. (2007). Transthyretin-derived amyloid deposition on the gastric mucosa in domino recipients of familial amyloid polyneuropathy liver. Liver Transpl, 13, 215-218.
158. Anderson, O., Wallin, G. (1992). Stationary course during sixteen months after liver transplantation in familial amyloidotic polyneuropathy. In Second International Symposium on Familial Amyloidotic Polyneuropathy and Other Transthyretin Related Disorders, Skelleftea, Sweden.
159. Foss, T.R., Wiseman, R.L., Kelly, J.W. (2005). The pathway by which the tetrameric protein transthyretin dissociates. Biochemistry, 44, 15525-15533.
160. Wiseman, R.L., Johnson, S.M., Kelker, M.S., Foss, T., Wilson, I.A., Kelly, J.W. (2005). Kinetic stabilization of an oligomeric protein by a single ligand binding event. J Am Chem Soc, 127, 5540-5551.
161. Johnson, S.M., Connelly, S., Wilson, I.A., Kelly, J.W. (2008). Toward optimization of the linker substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies. J Med Chem, 51, 6348-6358.
162. Johnson, S.M., Connelly, S., Wilson, I.A., Kelly, J.W. (2008). Biochemical and structural evaluation of highly selective 2-arylbenzoxazole-based transthyretin amyloidogenesis inhibitors. J Med Chem, 51, 260-270.
163. Adamski-Werner, S.L., Palaninathan, S.K., Sacchettini, J.C., Kelly, J.W. (2004). Diflunisal analogues stabilize the native state of transthyretin: potent inhibition of amyloidogenesis. J Med Chem, 47, 355-374.
164. Green, N.S., Palaninathan, S.K., Sacchettini, J.C., Kelly, J.W. (2003). Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization. J Am Chem Soc, 125, 13404-13414.
165. Johnson, S.M., Petrassi, H.M., Palaninathan, S.K., Mohamedmohaideen, N.N., Purkey, H.E., Nichols, C., Chiang, K.P., Walkup, T., Sacchettini, J.C., Sharpless, K.B., Kelly, J.W. (2005). Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation. J Med Chem, 48, 1576-1587.
166. Peterson, S.A., Klabunde, T., Lashuel, H., Purkey, H., Sacchettini, J.C., Kelly, J.W. (1998). Inhibiting transthyretin conformational changes that lead to amyloid fibril formation. Proc Natl Acad Sci U S A, 95, 12956-12960.
167. Petrassi, H.M., Klabunde, T., Sacchettini, J., Kelly, J.W. (2000). Structure-based design of N-phenyl phenoxazine transthyretin amyloid fibril inhibitors. J Am Chem Soc, 122, 2178-2192.
168. Purkey, H.E., Palaninathan, S.K., Kent, K.C., Smith, C., Safe, S.H., Sacchettini, J.C., Kelly, J.W. (2004). Hydroxylated polychlorinated biphenyls selectively bind transthyretin in blood and inhibit amyloidogenesis: rationalizing rodent PCB toxicity. Chem Biol, 11, 1719-1728.
169. Razavi, H., Palaninathan, S.K., Powers, E.T., Wiseman, R.L., Purkey, H.E., Mohamedmohaideen, N.N., Deechongkit, S., Chiang, K.P., Dendle, M.T., Sacchettini, J.C., Kelly, J.W. (2003). Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action. Angew Chem Int Ed Engl, 42, 2758-2761.
170. Sacchettini, J.C., Kelly, J.W. (2002). Therapeutic strategies for human amyloid diseases. Nat Rev Drug Discov, 1, 267-275.
171. Wojtczak, A., Cody, V., Luft, J.R., Pangborn, W. (1996). Structures of human transthyretin complexed with thyroxine at 2.0 A ° resolution and 3u,5u-dinitro-Nacetyl-L-thyronine at 2.2 A ° resolution. Acta Crystallogr D, 52, 758-765.
172. Petrassi, H.M., Johnson, S.M., Purkey, H.E., Chiang, K.P., Walkup, T., Jiang, X., Powers, E.T., Kelly, J.W. (2005). Potent and selective structure-based dibenzofuran inhibitors of transthyretin amyloidogenesis: kinetic stabilization of the native state. J Am Chem Soc, 127, 6662-6671.
173. Baures, P.W., Oza, V.B., Peterson, S.A., Kelly, J.W. (1999). Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the nonsteroidal antiinflammatory drug flufenamic acid. Bioorg Med Chem, 7, 1339-1347.
174. Baures, P.W., Peterson, S.A., Kelly, J.W. (1998). Discovering transthyretin amyloid fibril inhibitors by limited screening. Bioorg Med Chem, 6, 1389-1401.
175. McCammon, M.G., Scott, D.J., Keetch, C.A., Greene, L.H., Purkey, H.E., Petrassi, H.M., Kelly, J.W., Robinson, C.V. (2002). Screening transthyretin amyloid fibril inhibitors: characterization of novel multiprotein, multiligand complexes by mass spectrometry. Structure, 10, 851-863.
176. Miller, S.R., Sekijima, Y., Kelly, J.W. (2004). Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest, 84, 545-552.
177. Oza, V.B., Petrassi, H.M., Purkey, H.E., Kelly, J.W. (1999). Synthesis and evaluation of biaryl amines and benzylamines as inhibitors of TTR amyloid fibril formation. Book of Abstracts, 217th ACS National Meeting, Anaheim, CAl, Mar. 21-25, ORGN-447.
178. Oza, V.B., Petrassi, H.M., Purkey, H.E., Kelly, J.W. (1999). Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors. Bioorg Med Chem Lett, 9, 1-6.
179. Oza, V.B., Smith, C., Raman, P., Koepf, E.K., Lashuel, H.A., Petrassi, H.M., Chiang, K.P., Powers, E.T., Sachettinni, J., Kelly, J.W. (2002). Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors. J Med Chem, 45, 321-332.
180. Razavi, H., Powers, E.T., Purkey, H.E., Adamski-Werner, S.L., Chiang, K.P., Dendle, M.T., Kelly, J.W. (2005). Design, synthesis, and evaluation of oxazole transthyretin amyloidogenesis inhibitors. Bioorg Med Chem Lett, 15, 1075-1078.
181. Sekijima, Y., Dendle Maria, A., Kelly, J.W. (2006). Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid, 13, 236-249.
182. Tojo, K., Sekijima, Y., Kelly, J.W., Ikeda, S.-I. (2006). Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis. Neurosci Res, 56, 441-449.
183. Ferguson, R.N., Edelhoch, H., Saroff, H.A., Robbins, J. (1975). Negative cooperativity in the binding of thyroxine to human serum prealbumin. Biochemistry, 14, 282-289.
184. Neumann, P., Cody, V., Wojtczak, A. (2001). Structural basis of negative cooperativity in transthyretin. Acta Biochim Pol, 48, 867-875.
185. Purkey, H., Dorrrell, M.I., Kelly, J.W. (2001). Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma. Proc Natl Acad Sci USA, 98, 5566-5571.